The Ledger

BSX

Boston Scientific CorpHealth Careinsider_universe

Last close $44.14Jun 28, 2026

Day −0.21%

Currently held

Agent 6 — Options Momentumlong
1 contracts · PUT $46 exp Jul 16, 2026 · entry $3.04
+$13.90 unrealized

Everything we've seen

·Jun 29, 3:34 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 3:19 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 3:05 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 2:49 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 2:34 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 2:19 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 2:19 PMstreamnews
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
·Jun 29, 2:04 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 1:49 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 1:34 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 1:19 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 1:04 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 12:49 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 12:34 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 12:19 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 12:04 PMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 11:49 AMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 11:34 AMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 11:19 AMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 11:04 AMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
·Jun 29, 10:49 AMstreamnews
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
❖Jun 29, 7:16 AMnewsvia finnhub
Edwards wins FDA clearance for LAA clip, setting up competition with AtriCure and Medtronic
Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.
?Jun 29, 7:06 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 29, 7:06 AMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 29, 7:06 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 29, 7:06 AMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
❖Jun 29, 6:18 AMnewsvia finnhub
3 Value Stocks to Research Further
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
❖Jun 29, 6:00 AMnewsvia finnhub
Boston Scientific Corp (NYSE:BSX) Meets All Caviar Cruise Quality Criteria for Long-Term Investors
Boston Scientific (BSX) passes the Caviar Cruise quality screen with 27% ROIC, 34.7% EBIT growth, and strong cash flow. A durable long-term investment candidate.
❖Jun 27, 3:09 PMnewsvia finnhub
Is Boston Scientific (BSX) One of the Best Low Volatility Stocks to Buy Under $50?
Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]
❖Jun 26, 10:48 AMnewsvia finnhub
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 9.5% over the past six months while the S&P 500 was up 6.2%.
?Jun 26, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 26, 7:04 AMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 26, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 26, 7:03 AMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
❖Jun 25, 9:18 AMnewsvia finnhub
Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity
Boston Scientific has suffered a 50% share price decline amid decelerating growth, but fundamentals-based valuation now appears attractive. Read more here.
❖Jun 25, 7:58 AMnewsvia finnhub
TD Cowen Maintains a Buy Rating on Boston Scientific (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the Stocks Expected to Bounce Back According to Analysts. The stock has fallen more than 52% year-to-date, but the Street expects more than 65% upside from the current level. Recently, on June 16, TD Cowen analyst Josh Jennings maintained his Buy rating on Boston Scientific Corporation (NYSE:BSX) with […]
❖Jun 25, 7:34 AMnewsvia finnhub
Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $65
Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $75 to $65.
?Jun 25, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 25, 7:05 AMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 25, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 25, 7:03 AMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 24, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 24, 6:06 PMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 24, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
!Jun 24, 6:06 PMsignalseverity 0.24
Agent 4 — Dip Buyer (Frozen) — dip_skipped
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
?Jun 24, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 24, 6:06 PMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
❖Jun 24, 6:00 PMnewsvia finnhub
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Boston Scientific (BSX) closed at $44.46, indicating a -2.5% shift from the previous trading day.
❖Jun 24, 4:12 PMnewsvia finnhub
How a Targeted Valve Recall and Watchman Questions at Boston Scientific (BSX) Have Changed Its Investment Story
Earlier in June 2026, the US Food and Drug Administration posted a Class II, firm-initiated recall of 9,750 Boston Scientific Orca sterile, single-use air/water and suction valves (lot 38400303, expiring January 20, 2029) after higher-than-expected reports of suction buttons sticking during gastrointestinal endoscopy procedures. The recall, which is ongoing and affects nationwide US distribution, highlights how even accessory devices can create operational and regulatory pressures for a...
❖Jun 24, 3:15 PMnewsvia finnhub
Boston Scientific (BSX) Recalls Orca Valves Nationwide After Device Malfunction
Boston Scientific (NYSE:BSX) has initiated a nationwide recall of its Orca Single Use Air/Water and Suction Valves. The recall is voluntary and follows identification of a device malfunction affecting procedures across the United States. The action reflects a material operational event for the company, with implications for patient safety oversight. Boston Scientific is a major medical device company, so a recall tied to endoscopy accessories like the Orca Single Use Air/Water and Suction...
❖Jun 24, 10:10 AMnewsvia finnhub
Jefferies Maintains Buy on Boston Scientific, Lowers Price Target to $67
Jefferies analyst Matthew Taylor maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $100 to $67.
?Jun 24, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 24, 7:04 AMsignalseverity 0.22
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 24, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 24, 7:04 AMsignalseverity 0.22
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
❖Jun 23, 6:15 PMnewsvia finnhub
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
The latest trading day saw Boston Scientific (BSX) settling at $45.6, representing a +2.86% change from its previous close.
❖Jun 23, 5:00 PMnewsvia finnhub
Tuesday's after hours session: top gainers and losers
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
❖Jun 23, 2:11 PMnewsvia finnhub
The Cash-Flow Fortress The Stryker Stock Bears Keep Missing
While the market fixates on a disruptive quarter for Stryker stock, the company's powerful ability to convert profit into hard cash reveals a deeper, under-appreciated resilience.
❖Jun 23, 11:06 AMnewsvia finnhub
Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
Boston Scientific Corp. (NYSE:BSX) is one of the 10 oversold stocks offering high upside. On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level. The analyst retained an Overweight rating […]
?Jun 23, 11:06 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 529: {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":"req_011CcLQ6nzKZbkZqH8Jm2gLy"}
!Jun 23, 11:06 AMsignal
Agent 7 — Day Trader — analyze_failed
❖Jun 23, 10:41 AMnewsvia finnhub
Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”
Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down. A caller asked about Cramer’s thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline […]
❖Jun 23, 10:13 AMnewsvia finnhub
Is Procedure Growth Broad-Based Enough to Support ISRG's 2026 Outlook?
ISRG raises its 2026 outlook after strong Q1 results, but can broad-based procedure growth offset emerging headwinds in key U.S. and global markets?
?Jun 23, 10:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BSX is up 1.85% intraday, a meaningful but not outsized move. No headline catalyst is present, suggesting the move is driven by internal flow or broad sector strength rather than a specific news event. The macro backdrop shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations and a lower-rate environment — modestly supportive for long-duration-sensitive sectors including medical devices/healthcare equipment like BSX, as lower discount rates support valuation multiples. However, the tailwind from this macro factor is indirect and mild. With 345 minutes remaining (essentially a full remaining session), there is ample time for continuation, but also ample time for fade. The absence of a news catalyst slightly reduces conviction that the move has a fundamental driver sustaining it into the close. Overall, momentum is modestly positive with no clear reversal signal — a slight lean toward continuation is warranted, but this is a borderline setup.
!Jun 23, 10:01 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BSX is up 1.85% intraday, a meaningful but not outsized move. No headline catalyst is present, suggesting the move is driven by internal flow or broad sector strength rather than a specific news event. The macro backdrop shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations and a lower-rate environment — modestly supportive for long-duration-sensitive sectors including medical devices/healthcare equipment like BSX, as lower discount rates support valuation multiples. However, the tailwind from this macro factor is indirect and mild. With 345 minutes remaining (essentially a full remaining session), there is ample time for continuation, but also ample time for fade. The absence of a news catalyst slightly reduces conviction that the move has a fundamental driver sustaining it into the close. Overall, momentum is modestly positive with no clear reversal signal — a slight lean toward continuation is warranted, but this is a borderline setup.
❖Jun 23, 9:30 AMnewsvia finnhub
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
?Jun 23, 8:51 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 23, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 23, 7:04 AMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 23, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 23, 7:03 AMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
❖Jun 23, 6:00 AMnewsvia finnhub
Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.07% on an annualized basis producing an average annual return of 13.28%. Currently, Boston Scientific has a market capitalization of
?Jun 22, 7:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 22, 7:21 PMsignalseverity 0.24
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 22, 7:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
!Jun 22, 7:21 PMsignalseverity 0.24
Agent 4 — Dip Buyer (Frozen) — dip_skipped
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
?Jun 22, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 22, 6:06 PMsignalseverity 0.24
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 22, 3:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BSX is down 2.31% on a clear fundamental catalyst: Truist cut its price target citing doctors changing usage patterns for a key heart device — this is not a vague macro-driven move but a specific demand/volume concern that could prompt ongoing selling as more participants digest the news. The sell-side cut is recent (2:14 PM ET), meaning the information is still propagating through the market and late-session institutional flow may continue to push lower. However, with only 35 minutes remaining until forced close, there is limited runway for further downside, and a -2.31% move already prices in a meaningful portion of the news. Macro context (low inflation expectations, T5YIE 1.5σ below trend) is broadly neutral to slightly risk-supportive for equities, which creates a mild headwind against further selling but is not sector-specific to medical devices. No reversal pattern is evident — the move appears directional rather than a fade from morning highs. On balance, modest continuation probability: the catalyst is real and fresh, but time compression limits the expected additional move.
!Jun 22, 3:10 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BSX is down 2.31% on a clear fundamental catalyst: Truist cut its price target citing doctors changing usage patterns for a key heart device — this is not a vague macro-driven move but a specific demand/volume concern that could prompt ongoing selling as more participants digest the news. The sell-side cut is recent (2:14 PM ET), meaning the information is still propagating through the market and late-session institutional flow may continue to push lower. However, with only 35 minutes remaining until forced close, there is limited runway for further downside, and a -2.31% move already prices in a meaningful portion of the news. Macro context (low inflation expectations, T5YIE 1.5σ below trend) is broadly neutral to slightly risk-supportive for equities, which creates a mild headwind against further selling but is not sector-specific to medical devices. No reversal pattern is evident — the move appears directional rather than a fade from morning highs. On balance, modest continuation probability: the catalyst is real and fresh, but time compression limits the expected additional move.
?Jun 22, 11:20 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BSX is down ~2.09% intraday with no attributable headline, suggesting this is technical or flow-driven selling rather than a news-catalyzed event. The move is meaningful but sits at the lower bound of the 2-5% conviction range. Macro context shows 5-year inflation expectations printing 1.5σ below trend, which is modestly risk-supportive for equities broadly (lower inflation expectations can ease rate pressure), creating a slight headwind against further downside continuation. However, absence of a reversal catalyst or headline to trigger a bounce, combined with ~265 minutes remaining (ample time for momentum to persist into close), keeps continuation odds marginally above 0.5. No clear reversal signal (e.g., no gap fill, no obvious morning fade pattern mentioned), and the initial selling pressure may attract further intraday momentum sellers. Net assessment: mild continuation bias downward, but weak conviction — probability just clears the threshold.
!Jun 22, 11:20 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BSX is down ~2.09% intraday with no attributable headline, suggesting this is technical or flow-driven selling rather than a news-catalyzed event. The move is meaningful but sits at the lower bound of the 2-5% conviction range. Macro context shows 5-year inflation expectations printing 1.5σ below trend, which is modestly risk-supportive for equities broadly (lower inflation expectations can ease rate pressure), creating a slight headwind against further downside continuation. However, absence of a reversal catalyst or headline to trigger a bounce, combined with ~265 minutes remaining (ample time for momentum to persist into close), keeps continuation odds marginally above 0.5. No clear reversal signal (e.g., no gap fill, no obvious morning fade pattern mentioned), and the initial selling pressure may attract further intraday momentum sellers. Net assessment: mild continuation bias downward, but weak conviction — probability just clears the threshold.
❖Jun 22, 10:14 AMnewsvia finnhub
Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device
Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $85 to $64, while keeping its Buy rating on the stock. Richard Newitter, the analyst on record, cited a growing slowdown in demand […]
?Jun 22, 7:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 22, 7:05 AMsignalseverity 0.23
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 22, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 22, 7:05 AMsignalseverity 0.23
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
❖Jun 22, 4:01 AMnewsvia finnhub
Cramer Passes On NioCorp And SoundHound — But Says One Stock Is 'Time To Buy'
Jim Cramer recommends buying SOFI, and avoiding RIVN and BSX. He also says NIOBF is too speculative, but likes MP and INOD in the data engineering market.
?Jun 18, 6:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
!Jun 18, 6:21 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
?Jun 18, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 18, 6:05 PMsignalseverity 0.23
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 18, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
❖Jun 18, 4:30 PMnewsvia finnhub
Global ECG Patch and Holter Monitor Market Size/Share Worth USD 3.92 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global ECG Patch and Holter Monitor Market size & share revenue was valued at approximately USD 1.87 Billion in 2025 and is expected to reach USD 2.04 Billion in 2026 and is expected to reach around USD 3.92 Billion by 2035, at a CAGR of 9.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are iRhythm Technologies
❖Jun 18, 3:30 PMnewsvia finnhub
Lightning Round: It's time to buy SoFi, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: SoFi, Rivian, Tractor Supply, Datadog, Boston Scientific, and more.
?Jun 18, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 18, 7:03 AMsignalseverity 0.23
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 18, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 18, 7:03 AMsignalseverity 0.23
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
❖Jun 18, 7:01 AMnewsvia finnhub
This Undervalued Medical-Devices Stock Is Poised for a Rebound
Medtronic is deeply undervalued and a good bet for your portfolio. At the time, an uncertain growth outlook kept us from recommending the stock. Four months later, it’s time to retire the narrative of Medtronic as a perpetual laggard.
❖Jun 18, 6:00 AMnewsvia finnhub
Penumbra wins CE mark for Thunderbolt clot removal tech
The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.
?Jun 17, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
!Jun 17, 6:06 PMsignalseverity 0.23
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BSX is down 23.2% from its 30-day high following a below-expected Q1 outlook, which is an idiosyncratic fundamental catalyst (guidance disappointment) rather than pure sector/macro noise — the health care sector is actually outperforming the broader market on a 30-day basis (+1.35pts vs SPY), making this a single-stock issue. The options flow is bearish with a P/C ratio of 1.75 and elevated put volume (z=+0.51), reinforcing downside pressure. There are no insider cluster buys and no unusual call activity to offset the negative signals. The macro environment is broadly neutral (VIX at 34th percentile, 10Y at 4.43% just below the 4.5% threshold), and the absence of imminent earnings is a mild positive, but the net signal score is negative.
?Jun 17, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
!Jun 17, 6:05 PMsignalseverity 0.23
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BSX is down 23.2% from its 30-day high, driven by a below-expected Q1 outlook (headline sentiment -0.45), which represents a confirmed guidance-related negative catalyst rather than a purely macro or sector-wide move. The options flow is notably bearish with a P/C ratio of 1.75 and put volume at a positive z-score (0.51), suggesting directional put buying rather than simple hedging. The Health Care sector is relatively resilient (rank 4/11, +1.35pts vs SPY over 30d), meaning BSX's drop appears idiosyncratic — tied to its own fundamental guidance shortfall — rather than a sector-wide flush that would self-correct. There are no insider buys to provide a contrarian signal, and no unusual call volume to suggest informed accumulation.
?Jun 17, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
!Jun 17, 6:05 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
BSX's 23.2% drop from its 30-day high appears driven by a below-consensus Q1 outlook, which represents a meaningful negative catalyst rather than pure macro noise. Boston Scientific remains a fundamentally sound medtech company with diversified revenue streams, but a guidance miss of this magnitude typically signals near-term earnings pressure that can keep a stock suppressed for multiple quarters. The macro backdrop (a flattening yield curve 2.3σ below trend) is more relevant to banks and defensives, not medtech, so the drop is predominantly company-specific.
❖Jun 17, 6:00 PMnewsvia finnhub
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Boston Scientific (BSX) closed the most recent trading day at $44.95, moving 4.2% from the previous trading session.
?Jun 17, 3:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BSX is down ~4.1% intraday driven by a below-expected Q1 outlook headline — a fundamental catalyst that justifies the move. However, several factors push continuation probability below threshold: (1) Only 35 minutes remain until the forced close, severely limiting room for further downside to reach the +3% profit target; (2) A -4% move already represents substantial intraday displacement, increasing the likelihood that sellers are exhausted and early buyers are stepping in near session lows; (3) The macro backdrop (flattening yield curve, T10Y2Y at 2.3σ below trend) is more relevant to financials/defensives than medical devices — no clear macro tailwind for continued selling pressure on BSX specifically; (4) Guidance disappointments often see a 'sell the news, stabilize' pattern late in the session after the initial flush. The news is real and the move is meaningful, but the combination of limited time and extended move suggests fade risk outweighs continuation here. Probability just below 0.5 — no trade.
!Jun 17, 3:10 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
BSX is down ~4.1% intraday driven by a below-expected Q1 outlook headline — a fundamental catalyst that justifies the move. However, several factors push continuation probability below threshold: (1) Only 35 minutes remain until the forced close, severely limiting room for further downside to reach the +3% profit target; (2) A -4% move already represents substantial intraday displacement, increasing the likelihood that sellers are exhausted and early buyers are stepping in near session lows; (3) The macro backdrop (flattening yield curve, T10Y2Y at 2.3σ below trend) is more relevant to financials/defensives than medical devices — no clear macro tailwind for continued selling pressure on BSX specifically; (4) Guidance disappointments often see a 'sell the news, stabilize' pattern late in the session after the initial flush. The news is real and the move is meaningful, but the combination of limited time and extended move suggests fade risk outweighs continuation here. Probability just below 0.5 — no trade.
❖Jun 17, 10:12 AMnewsvia finnhub
Below Expected Outlook Pressured Boston Scientific (BSX) in Q1
Renaissance Investment Management, an investment management company, released its Q1 2026 “Large Cap Growth Strategy.” A copy of the letter can be downloaded here. Stocks fell sharply in the first quarter due to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. […]
?Jun 17, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
?Jun 17, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $7.99 cash available; close=$46.92.
❖Jun 17, 7:00 AMnewsvia finnhub
Medtech M&A maintains momentum following decade-high 2025: PwC
Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and Danaher’s Masimo acquisition.
?Jun 16, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.33 cash available; close=$46.92.
?Jun 16, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
?Jun 16, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX cut its FY26 guidance today, with the CEO citing three unanticipated factors at the Bernstein Conference, triggering a ~6% intraday drop and making it the worst-performing S&P 500 stock on the day. The 24.6% decline from its 30-day high reflects a genuine fundamental deterioration — a guidance cut is not macro noise but a company-specific earnings revision that typically requires multiple quarters to recover from. While BSX is investing $1.5B in a growth initiative that Wall Street is watching, that longer-term optionality does not offset the near-term earnings headwind from the guidance reduction.
?Jun 16, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.93 cash available; close=$46.76.
?Jun 16, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
❖Jun 16, 1:44 AMnewsvia finnhub
BTIG Reiterates Buy on Boston Scientific, Maintains $65 Price Target
BTIG analyst Marie Thibault reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $65 price target.
?Jun 15, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.35 cash available; close=$46.76.
?Jun 15, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
?Jun 15, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX cut its FY26 guidance today, with the CEO citing three unanticipated factors at the Bernstein Conference, triggering a ~6% intraday drop and making it the worst-performing S&P 500 stock on the day. The 24.6% decline from its 30-day high reflects a genuine fundamental deterioration — a guidance cut is not macro noise but a company-specific earnings revision that typically requires multiple quarters to recover from. While BSX is investing $1.5B in a growth initiative that Wall Street is watching, that longer-term optionality does not offset the near-term earnings headwind from the guidance reduction.
❖Jun 15, 2:38 PMnewsvia finnhub
If You’re Looking for the ‘Next Big Thing’ Before the OpenAI and Anthropic IPOs, Try This Barchart Stock Screener
Sometimes boring stocks can be the most exciting.
?Jun 15, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.19 cash available; close=$46.91.
?Jun 15, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
❖Jun 14, 10:53 PMnewsvia finnhub
Why Did ADBE, CHWY, BSX Slump To 52-Week Lows Last Week?
Adobe, Chewy, and Boston Scientific fell to 52-week lows on Friday after receiving multiple price target cuts from Wall Street analysts.
❖Jun 13, 11:29 AMnewsvia finnhub
Truist Reiterates Buy Rating for Boston Scientific (BSX)
Boston Scientific Corp. (NYSE:BSX) is one of the 12 best buy-the-dip stocks to invest in now. On June 4, Truist significantly decreased the price target on Boston Scientific Corp. (NYSE:BSX), from $85 to $64, while maintaining a Buy rating on the stock. The firm cited recent management remarks indicating that the Watchman device’s growth in […]
❖Jun 13, 3:17 AMnewsvia finnhub
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
Penumbra received FDA clearance for its Thunderbolt stroke thrombectomy device. Boston Scientific (NYSE:BSX) previously agreed to acquire Penumbra, with closing expected later this year. The clearance adds another device to the neurovascular and mechanical thrombectomy portfolio that Boston Scientific is set to own. For investors watching Boston Scientific, the Penumbra deal centers on expanding exposure to neurovascular care and stroke intervention. Thunderbolt now arrives as an FDA...
❖Jun 13, 12:35 AMnewsvia finnhub
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Analysts remain relatively more upbeat, but this could prove fleeting.
?Jun 12, 6:04 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
?Jun 12, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $13.51 cash available; close=$46.90.
?Jun 12, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
BSX cut its FY26 guidance today, with the CEO citing three unanticipated factors at the Bernstein Conference, triggering a ~6% intraday drop and making it the worst-performing S&P 500 stock on the day. The 24.6% decline from its 30-day high reflects a genuine fundamental deterioration — a guidance cut is not macro noise but a company-specific earnings revision that typically requires multiple quarters to recover from. While BSX is investing $1.5B in a growth initiative that Wall Street is watching, that longer-term optionality does not offset the near-term earnings headwind from the guidance reduction.
❖Jun 12, 11:34 AMnewsvia finnhub
FDA clears Penumbra’s Thunderbolt thrombectomy platform for stroke
Penumbra’s computer assisted vacuum thrombectomy platform uses aspiration for clot removal during acute ischemic stroke treatment.
✓Jun 12, 10:17 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
PUT on BSX — 5-day return -5.03% with close below 20-day MA ($51.13). IV 56.3%. Sized 1 contract(s) at $3.04 premium.
❖Jun 12, 7:49 AMnewsvia finnhub
Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One
Boston Scientific stock plunged ~53% on guidance cuts and WATCHMAN/EP issues, but trades cheap vs. peers. Click here to read my analysis on Boston Scientific.
❖Jun 12, 7:22 AMnewsvia finnhub
Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
The stroke treatment could contribute about $100 million in incremental revenue over time to Boston Scientific, the buyer of Penumbra, one analyst said.
?Jun 12, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $9.47 cash available; close=$47.17.
?Jun 12, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BSX (Boston Scientific) is a large-cap medical device leader with historically strong fundamentals — the 19.5% drop from its 30-day high lacks any identifiable confirmed catalyst (no negative news headlines, no SEC filings indicating impairment, no insider selling). The Health Care sector is actually outperforming SPY meaningfully (+7.41pts over 5 days, +4.33pts over 30 days, ranked 2nd of 11 sectors), suggesting this is an idiosyncratic pullback rather than a sector-wide rotation, which could indicate temporary price dislocation. Options flow is modestly balanced (P/C ratio 0.90, both volumes near z-score neutral), providing no strong directional signal either way but no alarming put pressure either.
❖Jun 11, 12:01 PMnewsvia finnhub
Elfun Trusts Exits Abbott Laboratories, Impacting Portfolio by -1.97%
Insightful Moves in Elfun Trusts (Trades, Portfolio)' First Quarter 2026 N-PORT Filing
❖Jun 11, 9:03 AMnewsvia finnhub
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 lowest forward P/E stocks in the S&P 500. Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority […]
❖Jun 10, 6:00 PMnewsvia finnhub
Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know
Boston Scientific (BSX) concluded the recent trading session at $48.34, signifying a -1.27% move from its prior day's close.
❖Jun 10, 3:30 PMnewsvia finnhub
[Latest] Global Gastrointestinal Endoscopy Devices Market Size/Share Worth USD 19.6 Billion by 2035 at a 5.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Gastrointestinal Endoscopy Devices Market size & share revenue was valued at approximately USD 11.6 Billion in 2025 and is expected to reach USD 12.2 Billion in 2026 and is expected to reach around USD 19.6 Billion by 2035, at a CAGR of 5.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are HOYA Corporatio
❖Jun 9, 1:26 PMnewsvia finnhub
Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman […]
▣Jun 8, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 300 @ $2.97 (-$11.14)
Stop: premium $2.97 ≤ trailing floor $3.07 (peak $4.10 × 0.75)
❖Jun 8, 6:00 AMnewsvia finnhub
Boston Scientific to build Indiana distribution center
The planned logistics site, near a principal manufacturing facility, will handle global distribution of Boston Scientific’s medical devices.
❖Jun 7, 11:45 PMnewsvia finnhub
Boston Scientific (BSX) Initiates $2B Accelerated Share Repurchase Agreement
Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million […]
❖Jun 6, 12:30 AMnewsvia finnhub
Medtronic: The Turnaround Is Quietly Working
Medtronic (MDT) outlook: mid-single-digit growth, stabilizing margins, and new drivers (Hugo, Affera). Read here for a detailed analysis.
❖Jun 5, 6:06 PMnewsvia finnhub
Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated […]
❖Jun 5, 1:11 PMnewsvia finnhub
How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...
▢Jun 4, 8:00 PMjournal
Agent 7 — Day Trader opened long 39 @ $48.85
▣Jun 4, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 39 @ $48.46 (-$15.21)
EOD forced close — day trader never carries overnight
❖Jun 4, 6:00 PMnewsvia finnhub
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
❖Jun 4, 9:30 AMnewsvia finnhub
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
▣May 28, 8:00 PMjournalstop
Agent 8 — Dip Buyer (Peer-Aware) closed long 41 @ $48.33 (-$178.55)
Stop hit: close $48.33 ≤ stop $48.47
▢May 27, 8:00 PMjournal
Agent 7 — Day Trader opened short 39 @ $48.55
▣May 27, 8:00 PMjournalstop
Agent 7 — Day Trader closed short 39 @ $49.28 (-$28.47)
Short stop: close $49.28 ≥ stop $49.28
▣May 26, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 300 @ $0.34 (-$681.54)
Stop: premium $0.34 ≤ trailing floor $2.34 (peak $3.12 × 0.75)
▣May 26, 8:00 PMjournalstop
Agent 4 — Dip Buyer (Frozen) closed long 38 @ $50.46 (-$241.87)
Stop hit: close $50.46 ≤ stop $52.28
▢May 26, 8:00 PMjournal
Agent 6 — Options Momentum opened long 300 @ $3.00
▢May 19, 8:00 PMjournal
Agent 6 — Options Momentum opened long 300 @ $2.61
▣May 18, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 300 @ $1.30 (-$440.71)
Stop: premium $1.30 ≤ trailing floor $2.27 (peak $3.03 × 0.75)
▢May 18, 8:00 PMjournal
Agent 5 — Dip Buyer (Evolving) opened long 46 @ $53.56
▣May 18, 8:00 PMjournalbank_funding
Agent 5 — Dip Buyer (Evolving) closed long 46 @ $56.69 (+$143.98)
Backfill 2026-05-19: closed at current mark to fund initial BANK sweep (highest unrealized P&L first; brings working equity to starting capital).
▢May 18, 8:00 PMjournal
Agent 4 — Dip Buyer (Frozen) opened long 38 @ $56.83
▢May 17, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 41 @ $52.68
▢May 13, 8:00 PMjournal
Agent 6 — Options Momentum opened long 300 @ $2.77

← Back to dashboard